Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PTC Therapeutics

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

Benzinga

PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for PTC Therapeutics shows improving technical performance.

Investors Business Daily

Stocks With Rising Relative Price Strength: PTC Therapeutics

A Relative Strength Rating upgrade for PTC Therapeutics shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

PTC Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating

PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Investors Business Daily

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Benzinga

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

PTC Therapeutics Stock Earns RS Rating Upgrade To 83

PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Investors Business Daily

PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble

European regulators rejected PTC Therapeutics' Duchenne muscular dystrophy drug — again — sending PTC stock into free fall early Friday.

Investors Business Daily

PTC Therapeutics Shows Rising Price Performance With Jump To 90 RS Rating

PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'

PTC stock opened at a nine-month high Monday after the EC decided against pulling its drug, Translarna, from the market.

Investors Business Daily

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72

PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug

PTC stock rose Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy.

Investors Business Daily

Biotech Crashes 30% After European Regulators Yank Approval For Muscle Disease Drug

European regulators voted against fully approving a muscular dystrophy treatment from PTC Therapeutics, and PTC stock crashed Friday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall As Market Rally Retreats Amid Debt-Ceiling Drama; Nvidia Earnings Due

The stock market retreated Tuesday, with many leaders slammed as debt-ceiling talks continue. Nvidia earnings loom large.

Investors Business Daily

PTC Therapeutics' Barrage Of Bad News Is Good News For Rival Reata Pharmaceuticals — Here's Why

PTC stock plummeted Wednesday and gave its closest rival a boost after the company's treatment for a neurological disorder flunked.

Barchart

Chart of the Day: PTC Therapeutics (PTCT) Upgraded To Buy by Zacks

The Chart of the Day belongs to the biopharmaceutical company PTC Therapeutics (PTCT) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Investors Business Daily

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

1,057 stories

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.